Page 1236 - Basic _ Clinical Pharmacology ( PDFDrive )

1222 Index

Kinins, 306–307 Lead poisoning, 1020–1025 Leukotriene B 4 (LTB 4 ), 326, 332, 356
biosynthesis of chelation for, 1030 Leukotriene C 4 (LTC 4 ), 324–325, 325f,
kallikreins in, 306, 306f epidemiology of, 1020 332
kininogens in, 306, 306f inorganic, 1021t, 1023–1025 Leukotriene D 4 (LTD 4 ), 325f, 332
formation and metabolism of, 306, 306f organolead, 1023, 1025 Leukotriene receptor antagonists
physiologic and pathologic effects of pharmacodynamics of, 1021–1023 asthma treated with, 336, 356f,
on cardiovascular system, 306 pharmacokinetics of, 1021, 1021t 356–357, 360, 362t
on endocrine and exocrine glands, 307 prevention of, 1024b preparations available, 363t
in hereditary angioedema, 307 treatment of, 1025 Leuprolide, 676, 683t
in inflammation and pain, 307 Lebrikizumab, 358 Leuprolide agonists, 972
Kisspeptin, 720 Lecithin:cholesterol acyltransferase (LCAT) Levetiracetam, 422–423, 433t, 436t
Kleine-Levin syndrome, 261 deficiency, 631 Levobunolol, 166. See also b-receptor
Ledipasvir, 888 antagonist drugs
L Leflunomide, 651, 988–989 Levobupivacaine, 460f, 470. See also
Labeled uses of drugs, 1153 Left ventricular dysfunction, atrial Anesthetics, local
Labetalol, 160, 164t, 166, 170t. See also fibrillation with, 228, 253 Levodopa, 151, 494–497, 508t
b-receptor antagonist drugs Legislation, drug, 15, 16t adverse effects of, 495–497
hypertension treated with, 183, 192t Leiomyomata, uterine, 677 chemistry of, 494
structure of, 163f Leishmaniasis drugs, 931–935, 932t–933t. clinical use of, 494–495
Lacosamide, 417–418, 433t, 435t See also Antiprotozoal drugs contraindications to, 497
Lactation nitazoxanide, 933–934 drug holidays from, 497
pharmacology of, 1055t, 1055–1056 pentamidine, 931, 933 drug interactions of, 497, 1167t
physiologic, dopamine agonists for, 679 preparations available, 936t mechanism of action of, 494
postpartum stimulation of, domperidone sodium stibogluconate, 930f, 932t, 933 pharmacokinetics of, 494, 496f
for, 1098 visceral prolactinemia treated with, 151
Lactulose, 1098 amphotericin, 935 Levofloxacin, 838–839, 843t
Lamivudine drug combinations, 935 Levomethadone, 588t
description of, 872t, 875 miltefosine, 935 Levomilnacipran, 537, 540, 550t. See also
hepatitis B treated with, 886–887 paromomycin, 935 Serotonin-norepinephrine
Lamotrigine, 529t Lenalidomide reuptake inhibitors (SNRIs)
bipolar disorder treated with, immunosuppressive uses of, 988 Levopropoxyphene, antitussive, 570, 572t
528, 529t multiple myeloma treated with, 971 Levorphanol, 555t, 568. See also Opioid
seizures treated with, 416f, 422, 433t, Lennox-Gastaut syndrome, seizures agonists
435t associated with Levosimendan
Lanreotide, 673, 683t clobazam for, 430 on calcium sensitivity, 213
Lansoprazole, 1091–1095. See also Proton- description of, 410 heart failure treated with, 219, 224
pump inhibitors (PPIs) felbamate for, 426 Levothyroxine (T 4 ), 690–692, 701t, 702.
Lanthanum carbonate, 784 lamotrigine for, 422, 435t See also Thyroid drugs
Lapatinib, 972 rufinamide for, 430, 436t Lewisite, 1025
Latanoprost (PGF 2α derivative), 323, 327 topiramate for, 427, 436t Lewy bodies, 493
Latrodectus mactans antivenom, equine, Lenograstim, 602–603 Lialda, 1107
1180t Lepirudin, 617 Licarbazepine, 417
Laxatives, 1098–1100, 1115t Leprosy drugs Lice, 1126t
bulk-forming, 1098 clofazimine, 851 Liddle’s syndrome, 266
chloride channel activators, 1099 dapsone and other sulfone, 850 Lidocaine, 460t, 462, 471, 472t. See also
opioid receptor antagonists, 1099–1100 rifampin, 851, 851t Anesthetics, local
osmotic Lethal dose arrhythmia treated with, 239t, 240t,
balanced polyethylene glycol, 1099 median (LD 50 ), 13, 37, 37f 241f, 241–242, 250t
nonabsorbable sugars or salts, 1098 minimum, 13 historical development of, 461b
OTC, 1125t–1126t Letrozole, 739 on ion channels, 560b
preparations available, 1117t Leukemia Ligand-gated channels
serotonin 5-HT 4 -receptor agonists, acute in central nervous system, 369f,
1100 adult, 969 369–370
stimulant, 1099 childhood, 969 description of, 29f, 29–30, 35
stool surfactant agents, 1098 chronic Ligand-regulated transmembrane enzymes,
LCAT, 631 lymphocytic, 970 27–28, 28f
L-DOPA, 369 myelogenous, 969–970 Linaclotide, 1099, 1103
Lead compound, 13 Leukotriene, 324f, 324–325 Linagliptin, 763, 769t